Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
NCT02372773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398
Last updated 2020-08-03
Summary
This study is being done to learn more about normal thinking and behavior, mild thinking and behavior problems, Frontotemporal Dementia and other forms of dementia in families in which one or more relatives have a mutation associated with Frontotemporal Dementia.
Conditions
- Familial Frontotemporal Dementia
Sponsors & Collaborators
-
National Institute on Aging (NIA)
collaborator NIH -
National Institute of Neurological Disorders and Stroke (NINDS)
collaborator NIH - lead OTHER
Principal Investigators
-
Bradley Boeve, MD · Mayo Clinic
-
Howard Rosen, MD · University of California, San Francisco
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-04-30
- Primary Completion
- 2020-06-30
- Completion
- 2020-06-30
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT03225144 ·Status: RECRUITING
-
Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders
NCT00001362 ·Status: COMPLETED
-
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Frontotemporal Dementia Initiative for Neurodevelopment
NCT05779813 ·Status: RECRUITING
-
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
NCT02707978 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT02103894 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
NCT02740634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
NCT06254469 ·Status: RECRUITING ·Phase: PHASE3
-
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT03373604 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
NCT06057909 ·Status: RECRUITING
-
Tau Imaging in Young Onset Dementia
NCT02289118 ·Status: COMPLETED
-
Neuroinflammation and Cognitive Decline in Alzheimer Disease
NCT02377206 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Optimization and Harmonization of Advanced MRI Sequences
NCT06217237 ·Status: COMPLETED
-
Diagnosing Frontotemporal Lobar Degeneration
NCT02964637 ·Status: RECRUITING
-
IGF and Other Neurotrophic Factors in Patients With Dementia
NCT02271750 ·Status: COMPLETED
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Epidemiological Study in FRONtoTemporal Dementia
NCT05075187 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT00159198 ·Status: TERMINATED
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
NCT02083367 ·Status: COMPLETED
-
A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test
NCT01322373 ·Status: UNKNOWN
-
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
NCT02317250 ·Status: WITHDRAWN ·Phase: PHASE3
-
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers
NCT04014673 ·Status: COMPLETED ·Phase: NA
-
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
NCT00887601 ·Status: COMPLETED ·Phase: PHASE1
-
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
NCT02759887 ·Status: COMPLETED ·Phase: NA